We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Commentary · December 09, 2021

2021 Top Story in Breast Cancer: Trastuzumab Deruxtecan: Revolutionizing Outcomes for Patients With HER2+ Breast Cancer

Written by
Paolo Tarantino MD
Sara M. Tolaney MD, MPH


Additional Info

  1. Tarantino P, Trapani D, Curigliano G. Mastering the use of novel anti-HER2 treatment options. JCO Oncol Pract. 2021;17(10):605-606.
  2. Pernas S, Tolaney SM. Management of early-stage human epidermal growth factor rreceptor 2–positive breast cancer. JCO Oncol Pract. 2021;17(6):320-330.
  3. Cortes J. ESMO 2021: Trastuzumab Deruxtecan Beats Trastuzumab Emtansine for HER2-Positive Metastatic Breast Cancer. Accessed on November 9, 2021.
  4. Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724-734.
  5. Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
  6. Piccart M, Procter M, Fumagalli D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up. J Clin Oncol. 2021;39(13):1448-1457.
  7. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-344.
  8. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-1791.
  9. Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610-621.
  10. Shitara K, Bang Y-J, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419-2430.
  11. Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. J Clin Oncol. 2020;38(suppl 15):9504.
  12. Siena S, Di Bartolomeo M, Raghav KPS, et al. A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. J Clin Oncol. 2020;38(suppl 15):4000.
  13. Cortes J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R. LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. Ann Oncol. 2021;32(suppl 5):S1283-S1346.
  14. Witzel I, Müller V, Abenhardt W, et al. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry. BMC Cancer. 2014;14(1):806.
  15. Yardley DA, Tripathy D, Brufsky AM, et al. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014;110(11):2756-2764.
  16. Tolaney SM, Barroso-Sousa R, Jiang Z, Park YH, Rimawi MF, Saura C. 328TiP Phase III study of trastuzumab deruxtecan with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line, HER2+ metastatic breast cancer: DESTINY-Breast09. Ann Oncol. 2021;32(suppl 5):S507-S508.
  17. Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951-1962.

Disclosure statements are available on the authors' profiles:

Further Reading